Results 41 to 50 of about 2,631 (192)

Involvement of Renal Efflux Transporter MATE1 in Renal Excretion of Flecainide

Biological and Pharmaceutical Bulletin, 2019
Flecainide, an anti-arrhythmic drug, undergoes renal excretion through active renal tubular secretion in addition to passive glomerular filtration. The contribution of renal uptake and efflux transporters in active renal tubular secretion of flecainide remains unclear except that flecainide is a substrate of human multidrug resistance protein 1 (MDR1).
Doki, Kosuke, Apáti, Sándor, Sakata, Takeshi, Homma, Masato   +3 more
openaire   +3 more sources

Renal Tubular Secretion of Dofetilide is Dependent on MATE1 Function

The FASEB Journal, 2020
Background Dofetilide is a delayed rectifier potassium channel inhibitor used to treat patients with atrial fibrillation and flutter. The clinical use of this drug is associated with increases in QTc interval, which can exacerbate cardiac arrhythmias.
Muhammad Erfan Uddin, Qiang Fu, Alice A Gibson, Ingrid M Bonilla, Cynthia A Carnes, Shuiying Hu, Alex Sparreboom   +6 more
openaire   +1 more source

Platinum–Acridine Agents with High Activity in Cancers Expressing the Solute Carrier MATE1 (SLC47A1)

, 2023
Platinum–acridine anticancer agents (PAs) containing acyclic (1 and 3) and heterocyclic (R)-3-aminopiperidine (2) and 2-iminopyrrolidine (4) based linker moieties were studied.
Shenjie Zhang, Cynthia S. Day (1336956), Haoqing Wu, Shenjie Zhang (15139461), Haoqing Wu (16647487), Cynthia S. Day, Ulrich Bierbach, Ulrich Bierbach (11002)   +7 more
core   +1 more source

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Clinical and Translational Science, 2022
Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in
Chia‐Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin, Ahmed A. Othman   +5 more
doaj   +1 more source

Relationship between DNA Methylation in the 5′ CpG Island of the SLC47A1 (Multidrug and Toxin Extrusion Protein MATE1) Gene and Interindividual Variability in MATE1 Expression in the Human Liver [PDF]

Molecular Pharmacology, 2018
Multidrug and toxin extrusion protein 1 (MATE1), which is encoded by solute carrier 47A1 (SLC47A1), mediates the excretion of organic cations into bile and urine. Some genetic variants in human MATE1 altered its transport function in in vitro experiments; however, differences in the pharmacokinetics of substrate drugs cannot be explained by genetic ...
Toshihiro, Tanaka, Takeshi, Hirota, Ichiro, Ieiri   +2 more
openaire   +2 more sources

Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells

, 2022
MATE1 (multidrug and toxin extruder 1) and OCT2 (organic cation transporter 2) play critical roles in organic cation excretion by the human kidney. The transporter turnover rate (TOR) is relevant to understanding both their transport mechanisms and ...
Wright, S.H., Xiaohong Zhang, Stephen H. Wright, Zhang, X.   +3 more
core   +1 more source

Region-specific blood–brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s disease

Fluids and Barriers of the CNS, 2019
Background Research into amisulpride use in Alzheimer’s disease (AD) implicates blood–brain barrier (BBB) dysfunction in antipsychotic sensitivity. Research into BBB transporters has been mainly directed towards the ABC superfamily, however, solute ...
Gayathri Nair Sekhar, Alice L. Fleckney, Sevda Tomova Boyanova, Huzefa Rupawala, Rachel Lo, Hao Wang, Doaa B. Farag, Khondaker Miraz Rahman, Martin Broadstock, Suzanne Reeves, Sarah Ann Thomas   +10 more
doaj   +1 more source

Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients

Chinese Journal of Cancer, 2016
Background Platinum-based chemotherapy is the first-line treatment of non-small cell lung cancer (NSCLC); it is therefore important to discover biomarkers that can be used to predict the efficacy and toxicity of this treatment. Four important transporter
Chen-Yue Qian, Yi Zheng, Ying Wang, Juan Chen, Jun-Yan Liu, Hong-Hao Zhou, Ji-Ye Yin, Zhao-Qian Liu   +7 more
doaj   +1 more source

In vitro cytochrome P450‐ and transporter‐mediated drug interaction potential of 6β‐hydroxy‐21‐desacetyl deflazacort—A major human metabolite of deflazacort

Pharmacology Research & Perspectives, 2021
6β‐Hydroxy‐21‐desacetyl deflazacort (6β‐OH‐21‐desDFZ) is a major circulating but not biologically active metabolite of deflazacort (DFZ). In vitro studies were performed to evaluate cytochrome P450 (CYP)‐ and transporter‐mediated drug interaction ...
Jiyuan Ma, Brian Beers, Ravi Manohar, Stephen Roe, Joseph M. Colacino, Ronald Kong   +5 more
doaj   +1 more source

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

Frontiers in Pharmacology, 2021
The kidneys are a pair of important organs that excretes endogenous waste and exogenous biological agents from the body. Numerous transporters are involved in the excretion process.
Wei Zou, Birui Shi, Ting Zeng, Yan Zhang, Baolin Huang, Bo Ouyang, Zheng Cai, Zheng Cai, Menghua Liu, Menghua Liu   +9 more
doaj   +1 more source